APA (7th ed.) Citation

JH, Y., JH, L., DH, Y., JW, C., JM, B., KH, Y., . . . S, L. (2026). Real-world outcomes of inotuzumab ozogamicin treatment for adult relapsed or refractory acute lymphoblastic leukemia: A result from Korea post-marketing surveillance. Annals of hematology, 105(3), 91. https://doi.org/10.1007/s00277-026-06838-z

Chicago Style (17th ed.) Citation

JH, Yoon, Lee JH, Yang DH, Cheong JW, Byun JM, Yoo KH, Woo J, Kim YM, and Lee S. "Real-world Outcomes of Inotuzumab Ozogamicin Treatment for Adult Relapsed or Refractory Acute Lymphoblastic Leukemia: A Result from Korea Post-marketing Surveillance." Annals of Hematology 105, no. 3 (2026): 91. https://doi.org/10.1007/s00277-026-06838-z.

MLA (9th ed.) Citation

JH, Yoon, et al. "Real-world Outcomes of Inotuzumab Ozogamicin Treatment for Adult Relapsed or Refractory Acute Lymphoblastic Leukemia: A Result from Korea Post-marketing Surveillance." Annals of Hematology, vol. 105, no. 3, 2026, p. 91, https://doi.org/10.1007/s00277-026-06838-z.